Cargando…
Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
Cholangiocarcinoma (CCA) is a malignant tumor with poor prognosis and high recurrence rate. There is no standard treatment for advanced CCA beyond first-line chemotherapy, which provides only limited benefits. In this study, we report a case of a postoperative recurrence ECC patient harboring a brea...
Autores principales: | Li, Wenxin, Ma, Zuohong, Fu, Xibo, Hao, Zhiqiang, Shang, Hai, Shi, Junping, Lei, Mengping, Xu, Mian, Ning, Shili, Hua, Xiangdong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506765/ https://www.ncbi.nlm.nih.gov/pubmed/34734039 http://dx.doi.org/10.21037/atm-21-3681 |
Ejemplares similares
-
Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation
por: Su, Yu-Li, et al.
Publicado: (2021) -
Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
por: Cheng, Yuan, et al.
Publicado: (2018) -
Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
por: Li, Xiaofen, et al.
Publicado: (2021) -
Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017) -
Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report
por: Zhang, Li, et al.
Publicado: (2021)